Zenarestat (FK-366; FR-74366) is an aldose reductase inhibitor. It was investigated as a treatment of diabetic neuropathy and cataract, but its development was terminated.[1]

Zenarestat
Names
Preferred IUPAC name
{3-[(4-Bromo-2-fluorophenyl)methyl]-7-chloro-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}acetic acid
Identifiers
3D model (JSmol)
ChemSpider
KEGG
UNII
  • InChI=1S/C17H11BrClFN2O4/c18-10-2-1-9(13(20)5-10)7-22-16(25)12-4-3-11(19)6-14(12)21(17(22)26)8-15(23)24/h1-6H,7-8H2,(H,23,24)
    Key: SXONDGSPUVNZLO-UHFFFAOYSA-N
  • InChI=1/C17H11BrClFN2O4/c18-10-2-1-9(13(20)5-10)7-22-16(25)12-4-3-11(19)6-14(12)21(17(22)26)8-15(23)24/h1-6H,7-8H2,(H,23,24)
    Key: SXONDGSPUVNZLO-UHFFFAOYAB
  • C1=CC2=C(C=C1Cl)N(C(=O)N(C2=O)CC3=C(C=C(C=C3)Br)F)CC(=O)O
Properties
C17H11BrClFN2O4
Molar mass 441.64 g/mol
Melting point 223 to 224 °C (433 to 435 °F; 496 to 497 K)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

References

edit
  • M. Hashimoto et al., EP 218999; eidem, US 4734419 (1987, 1988 both to Fujisawa)
  • Inhibition kinetics and effect on sorbitol accumulation: S. Ao et al., Metabolism 40, 77 (1991)
  • Pharmacokinetics and metabolism in diabetic rats: Y. Tanaka et al., Drug Metab. Dispos. 21, 677 (1993)
  • M. Kanamaru et al., J. Clin. Pharmacol. 33, 1122 (1993).


  1. ^ "Zenarestat — AdisInsight". Adis Insight. Springer International Publishing AG. Retrieved 3 January 2016.